WO2012121529A3 - Composition pour la régénération des cellules nerveuses ou la régénération des cellules endothéliales comprenant un agent de suppression de l'action de la ninjurine - Google Patents

Composition pour la régénération des cellules nerveuses ou la régénération des cellules endothéliales comprenant un agent de suppression de l'action de la ninjurine Download PDF

Info

Publication number
WO2012121529A3
WO2012121529A3 PCT/KR2012/001621 KR2012001621W WO2012121529A3 WO 2012121529 A3 WO2012121529 A3 WO 2012121529A3 KR 2012001621 W KR2012001621 W KR 2012001621W WO 2012121529 A3 WO2012121529 A3 WO 2012121529A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
ninjurin
endothelial
nerve
suppressing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/001621
Other languages
English (en)
Korean (ko)
Other versions
WO2012121529A2 (fr
Inventor
김규원
안범주
서준규
류지간
김우진
윤국남
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Inha Industry Partnership Institute
Inha University Research and Business Foundation
Original Assignee
SNU R&DB Foundation
Inha Industry Partnership Institute
Inha University Research and Business Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SNU R&DB Foundation, Inha Industry Partnership Institute, Inha University Research and Business Foundation filed Critical SNU R&DB Foundation
Publication of WO2012121529A2 publication Critical patent/WO2012121529A2/fr
Publication of WO2012121529A3 publication Critical patent/WO2012121529A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pour la régénération des cellules nerveuses ou des cellules endothéliales comprenant un agent de suppression de l'action de la ninjurine en tant que substance active. Plus spécifiquement, la présente invention concerne une composition pharmaceutique pour prévenir et/ou traiter un dysfonctionnement érectile comprenant un agent de suppression de l'action de la ninjurine. L'agent de suppression de l'action de la ninjurine de la présente invention a une action de régénération des cellules nerveuses et/ou cellules endothéliales et peut être utilisé pour prévenir et/ou traiter un dysfonctionnement érectile par induction de la croissance de cellules nerveuses et/ou cellules endothéliales dans le pénis. De plus, la présente invention devrait puisqu'elle permet de traiter avoir un effet thérapeutique relativement prolongé fondamentalement des nerfs et des structures de vaisseau sanguin qui sont devenus anormaux.
PCT/KR2012/001621 2011-03-07 2012-03-05 Composition pour la régénération des cellules nerveuses ou la régénération des cellules endothéliales comprenant un agent de suppression de l'action de la ninjurine Ceased WO2012121529A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0019767 2011-03-07
KR1020110019767A KR101277873B1 (ko) 2011-03-07 2011-03-07 Ｎｉｎｊｕｒｉｎ 활성 억제제를 포함하는 신경세포 또는 내피세포 재생용 조성물

Publications (2)

Publication Number Publication Date
WO2012121529A2 WO2012121529A2 (fr) 2012-09-13
WO2012121529A3 true WO2012121529A3 (fr) 2012-12-13

Family

ID=46798641

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001621 Ceased WO2012121529A2 (fr) 2011-03-07 2012-03-05 Composition pour la régénération des cellules nerveuses ou la régénération des cellules endothéliales comprenant un agent de suppression de l'action de la ninjurine

Country Status (2)

Country Link
KR (1) KR101277873B1 (fr)
WO (1) WO2012121529A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230050798A (ko) 2021-10-08 2023-04-17 김형우 길이 조절이 가능한 멀티탭

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100065953A (ko) * 2008-12-09 2010-06-17 서울대학교산학협력단 Ｎｉｎｊｕｒｉｎ１ 발현 또는 활성 억제제를 함유하는 염증성 질환 예방 및 치료용 조성물
US20100310568A1 (en) * 2009-06-09 2010-12-09 Alexandre Prat Ninjurin-1 modulation and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100377022B1 (ko) * 2000-07-05 2003-03-26 한국생명공학연구원 인체 신경손상 유도 단백질에 대한 단일클론 항체 및 이를생산하는 융합세포주

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100065953A (ko) * 2008-12-09 2010-06-17 서울대학교산학협력단 Ｎｉｎｊｕｒｉｎ１ 발현 또는 활성 억제제를 함유하는 염증성 질환 예방 및 치료용 조성물
US20100310568A1 (en) * 2009-06-09 2010-12-09 Alexandre Prat Ninjurin-1 modulation and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAE WHA KIM ET AL.: "Up-regulation ofninjurin expression in human in hepatocellular carcinoma associated with cirrhosis and chronic viral hepatitis", MOLECULES AND CELLS, vol. 11, no. 2, 2001, pages 151 - 157 *
TOSHIYUKI ARAKI ET AL.: "Mechanism ofhomophilic binding mediated by ninjurin, a novel widely expressed adhesion molecule", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 34, 1997, pages 21373 - 21380 *

Also Published As

Publication number Publication date
KR101277873B1 (ko) 2013-07-26
KR20120101762A (ko) 2012-09-17
WO2012121529A2 (fr) 2012-09-13

Similar Documents

Publication Publication Date Title
GB2491775A (en) Pulsatile drug release
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
GB2491328A (en) Immediate/delayed drug delivery
GB2491327A (en) Delayed prolonged drug delivery
WO2010081091A3 (fr) Compositions thérapeutiques pour le traitement de troubles de la cornée
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
EA201490495A1 (ru) Новые легкоразрушающиеся ингибиторы rock
MX2013005543A (es) Metodo para el tratamiento de nefropatia inducida por contraste.
EP2490700A4 (fr) Composition de soin externe pour la peau comprenant un sel et du sucre en tant que principes actifs pour prévenir et traiter la vaginose et utilisation de cette composition
PH12013501750A1 (en) Guanidine compound
WO2011139794A3 (fr) Composition pour le nettoyage et la protection de la peau et son procédé d'utilisation
WO2013169864A3 (fr) Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie
WO2012080497A3 (fr) Procédés de traitement et de prévention de maladies oculaires
IN2014DN10548A (fr)
MX338554B (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
HK1215934A1 (zh) 肽治疗剂及其使用方法
SA113340494B1 (ar) تركيبة لعلاج اضطرابات أيضية
WO2011153458A3 (fr) Compositions et méthodes utilisables en vue de l'inhibition ou du traitement d'une infection par le virus de la dengue
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.
WO2015063613A3 (fr) Corps d'inclusion pour administration transdermique d'agents thérapeutiques et cosmétiques
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
WO2013038200A3 (fr) Troubles neurodéveloppementaux
GB201312583D0 (en) Combination and composition for treating obesity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12754663

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12754663

Country of ref document: EP

Kind code of ref document: A2